GPAT 2011: Important Dates

Friends, finally the date of the war has been announced...so, start sharpening your weapons for GPAT 2011.

Details:

• Registration for GPAT – 2011 examination will be ONLINE.
• The GPAT – 2011 examination will be at selected centers throughout India.
• The GPAT – 2011 examination will have multiple choice question ( MCQs ) as GPAT – 2010.
• The syllabus of GPAT – 2011 examination has been revised.

TENTATIVE SCHEDULE:

Online Application website opens	Monday, 17th January 2011
Online Application website closes	Monday, 21st February 2011
Last date of receipt of photo, signature, Bank challan as a proof of payment for examination fees along with the printout of application	Monday, 28th February 2011
Date of Examination	Sunday, 8th May 2011

SYLLABUS FOR GPAT-2011:

click the link : http://gpat.in/index.php?gpat=syllabus11


For more Details :

 log on to www.gpat.in

All the Best Guys!!
:)

Read More

Pharma's Top 10 Blockbuster Drugs

Pharma's Top 10 Blockbuster Drugs

1) Lipitor(Atorvastatin)

• Maker: Pfizer
• Sales Rank: 1
• Technology: Chiral chemistry
• 2009 Sales: $12.5 billion
• Indications: Hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) to reduce total cholesterol.

2) Plavix (clopidogrel)

• Maker: Bristol-Myers Squibb and Sanofi-Aventis.
• Sales Rank: 2
• Technology: Small molecule.
• 2009 Sales: $9.5 billion.
• Indications: Heart attack and stroke prevention.

3) Advair (fluticasone and salmeterol)

• Maker: GlaxoSmithKline
• Sales Rank: 3
• Technology: Small Molecule
• 2009 Sales: $7.7 billion
• Indications: Asthma and COPD.

4) Enbrel ( Etanercept)

• Maker: Amgen
• Sales Rank: 4
• Technology: Recombinant product
• 2009 Sales: $6.2 billion
• Indications: Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, chronic plaque psoriasis.

5) Diovan (valsartan)

• Maker: Novartis
• Sales Rank: 5
• Technology: Small Molecule
• 2009 Sales: $6.0 billion
• Indications: Hypertension and congestive heart failure.

6) Remicade ( Infliximab)

• Maker: Johnson & Johnson
• Sales Rank: 6
• Technology: Monoclonal antibody
• 2009 Sales: $5.9 billion
• Indications: Plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults, pediatric Crohn's disease, ulcerative colitis, and ankylosing spondylitis.

7) Avastin ( Bevacizumab)

• Maker:  Roche/Genentech
• Sales Rank: 7
• Technology: Monoclonal antibody
• 2009 Sales: $5.7 billion
• Indications: Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Glioblastoma, Metastatic Kidney Cancer.

8) Rituxan ( Rituximab)

• Maker:  Roche/Genentech
• Sales Rank: 8
• Technology: Monoclonal antibody
• 2009 Sales: $5.6 billion
• Indications: Non-Hodgkin's lymphoma, Chronic Lymhocytic leukemia, Rheumatoid arthritis.

9) Humira ( Adalimumab)

• Maker: Abbott Pharmaceuticals
• Sales Rank: 9
• Technology: Monoclonal antibody
• 2009 Sales: $5.5 billion
• Indications: Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis (AS) in adults, Crohn's disease, Plaque psoriasis.

10) Seroquel ( Quetiapine fumarate)

• Maker: AstraZeneca
• Sales Rank: 10
• Technology: Small molecule
• 2009 Sales: $5.1 billion
• Indications: Major depressive disorder, Acute depressive episodes in bipolar disorder, Acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; Long-term treatment of bipolar disorder with lithium or divalproex, and Schizophrenia.

The list is brought out by:-
FiercePharma, EvaluatePharma and PriceWaterhouse Coopers.(jointly)

Read More